← Back to home

Dupixent Profits Lift Regeneron Past Wall Street Forecasts

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Regeneron's revenue grew 36% to $5.12 billion in the third quarter, the drugmaker said Friday.

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

2 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home